MARKET

KMPH

KMPH

KemPharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2281
+0.0091
+4.16%
After Hours: 0.2199 -0.0082 -3.59% 17:48 03/27 EDT
OPEN
0.2210
PREV CLOSE
0.2190
HIGH
0.2390
LOW
0.2100
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
2.000
52 WEEK LOW
0.1800
MARKET CAP
11.56M
P/E (TTM)
-0.2620
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KMPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KMPH stock price target is 5.25 with a high estimate of 8.00 and a low estimate of 2.500.

EPS

KMPH News

More
  • 90 Biggest Movers From Yesterday
  • Benzinga · 03/12 10:10
  • 78 Stocks Moving In Wednesday's Mid-Day Session
  • Benzinga · 03/11 16:12
  • 26 Stocks Moving in Wednesday's Pre-Market Session
  • Benzinga · 03/11 11:54
  • The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
  • Benzinga · 03/10 13:19

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About KMPH

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
More

Webull offers kinds of KemPharm Inc stock information, including NASDAQ:KMPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KMPH stock news, and many more online research tools to help you make informed decisions.